Clinical Trial Update: Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating pembrolizumab in combination with lanreotide depot for gastroenteropancreatic neuroendocrine tumors has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumors

Drugs mentioned

• Lanreotide Depot (lanreotide)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Duke University | Conditions: Gastroenteropancreatic Neuroendocrine Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-09-28